DRAFLAZINE

Details

Stereochemistry	RACEMIC
Molecular Formula	C30H33Cl2F2N5O2
Molecular Weight	604.518
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=O)C1CN(CCCCC(C2=CC=C(F)C=C2)C3=CC=C(F)C=C3)CCN1CC(=O)NC4=C(Cl)C=C(N)C=C4Cl

InChI

InChIKey=IWMYIWLIESDFRZ-UHFFFAOYSA-N

InChI=1S/C30H33Cl2F2N5O2/c31-25-15-23(35)16-26(32)29(25)37-28(40)18-39-14-13-38(17-27(39)30(36)41)12-2-1-3-24(19-4-8-21(33)9-5-19)20-6-10-22(34)11-7-20/h4-11,15-16,24,27H,1-3,12-14,17-18,35H2,(H2,36,41)(H,37,40)

HIDE SMILES / InChI

Molecular Formula	C30H33Cl2F2N5O2
Molecular Weight	604.518
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: DOI: 10.1016/B978-008055232-3.61656-3 | https://adisinsight.springer.com/drugs/800002171 | https://www.ncbi.nlm.nih.gov/pubmed/24162843

Draflazine is a member of the lidoflazine. Draflazine is a potent inhibitor of equilibrative nucleoside transporters (ENTs). It is more selective for ENT1 relative to ENT2. Draflazine is cardioprotective due to potentiation of receptor-mediated effects of adenosine in the ischemic myocardium. It has also been tested for enhancing cardiac functionality in isolated hearts during storage or transport for transplant operations. Draflazine exhibits overactive bladder activity. It is not yet approved for clinical use.

Approval Year

PubMed

Title	Date	PubMed
Lack of the nucleoside transporter ENT1 results in the Augustine-null blood type and ectopic mineralization.	2015-06-04	25896650
Loss of equilibrative nucleoside transporter 1 in mice leads to progressive ectopic mineralization of spinal tissues resembling diffuse idiopathic skeletal hyperostosis in humans.	2013-05	23184610
Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1).	2011-09-16	21795683
Interaction of the novel adenosine uptake inhibitor 3-[1-(6,7-diethoxy-2-morpholinoquinazolin-4-yl)piperidin-4-yl]-1,6-dimethyl-2,4(1H,3H)-quinazolinedione hydrochloride (KF24345) with the es and ei subtypes of equilibrative nucleoside transporters.	2004-03	14634039
Interaction of a series of draflazine analogues with equilibrative nucleoside transporters: species differences and transporter subtype selectivity.	2000-04	10763851
Chimeric constructs between human and rat equilibrative nucleoside transporters (hENT1 and rENT1) reveal hENT1 structural domains interacting with coronary vasoactive drugs.	1998-08-21	9705281

Sample Use Guides

In Vivo Use Guide

Single dose - 10 mg/kg

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:02:56 GMT 2025` Edited by `admin` on `Mon Mar 31 18:02:56 GMT 2025`
Record UNII	0Y25DT968Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

R-70380

Preferred Name

English

DRAFLAZINE

Official Name

English

(±)-4'-AMINO-4-(5,5-BIS(P-FLUOROPHENYL)PENTYL)-2-CARBAMOYL-2',6'-DICHLORO-1-PIPERAZINEACETANILIDE

Common Name

English

2-(AMINOCARBONYL)-N-(4-AMINO-2,6-DICHLOROPHENYL)-4-(5,5-BIS(4-FLUOROPHENYL)PENTYL)-1-PIPERAZINEACETAMIDE

Systematic Name

English

R70380

Code

English

R-75231

Code

English

(±)-2-(AMINOCARBONYL)-N-(4-AMINO-2,6-DICHLOROPHENYL)-4-(5,5-BIS(4-FLUOROPHENYL)PENTYL)-1-PIPERAZINE-ACETAMIDE

Systematic Name

English

draflazine [INN]

Common Name

English

R75231

Code

English

1-PIPERAZINEACETAMIDE, 2-(AMINOCARBONYL)-N-(4-AMINO-2,6-DICHLOROPHENYL)-4-(5,5-BIS(4-FLUOROPHENYL)PENTYL)-, (±)-

Systematic Name

English

DRAFLAZINE [USAN]

Common Name

English

1-PIPERAZINEACETAMIDE, 2-(AMINOCARBONYL)-N-(4-AMINO-2,6-DICHLOROPHENYL)-4-(5,5-BIS(4-FLUOROPHENYL)PENTYL)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1327